The presence of insoluble protein aggregates is a pathological hallmark of neurodegenerative disorders such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease, Huntington's disease and prion protein disorders. In synucleinopathies such as PD and DLB, the Lewy body is the pathological protein aggregate that is found in the cytoplasm of susceptible neuronal populations. Lewy bodies are eosinophilic inclusions containing numerous aggregated proteins, including alpha-synuclein (1syn), which suggests a causative role for this protein in these disorders. Misfolding and aggregation of 1syn are thought to be critical cofactors linked to disease development. In particular, the accumulation of nonfibrillar dimers and oligomers of 1syn, which serve as intermediates for fibrillar Lewy body formation, is thought to cause neurodegeneration. Because oligomeric forms of 1syn are believed toxic to cells, an important therapeutic strategy will be to reduce oligomer formation or prevent it altogether. In this application we propose to study the role of oligomeric 1syn in synucleinopathies and examine how specific modifications affect toxicity and oligomer formation. To enable the direct study of 1syn oligomerization, we have applied novel strategies including protein complementation assays (PCAs), size exclusion chromatography (SEC) and fluorescence correlation spectroscopy (FCS) by which to identify and follow 1syn oligomer formation, thus providing a powerful toolbox of techniques with which to study manipulations affecting 1syn-induced toxicity. This application is divided into three coordinated and related aims that will characterize 1syn oligomers and investigate the role of 1syn oligomers in disease pathogenesis with a view to determining the effect of disease- related modifications and molecular chaperones on 1syn oligomer formation and subcellular location (aim 1 &2). We also propose to recapitulate 1syn oligomerization in vivo via stereotactic injection of recombinant adeno-associated virus and examine the resulting toxicity and subcellular localization of 1syn oligomers in vivo, as well as the effect of molecular chaperone interventions identified in aim 2 (aim 3). We propose that this application offers an effective strategy by which to identify and modulate 1syn oligomer formation, and targets therapeutics to a pre-toxic stage of fibrillization, where rescue of the soluble, monomeric forms of 1syn can substantially impact disease progression. If successful, the experiments described will significantly advance the study of 1syn-induced toxicity and related oligomer formation, and contribute to the development of successful therapeutic strategies to treat PD and related disorders. Thus, this study is in accordance with the mission of NINDS - to reduce the burden of neurological disease.

Public Health Relevance

A common feature of neurodegenerative diseases is the excessive accumulation of "misfolded" proteins and a disruption in cellular function. There is strong evidence to suggest that alpha-synuclein (1syn) accumulation is an early step in the development of both sporadic and inherited Parkinson disease (PD). Because 1syn accumulates and aggregates in neurons, we hypothesize that a complete understanding of 1syn misfolding, oligomerization and aggregation will be crucial to the development of new therapeutic strategies for the treatment of PD and related synucleinopathies. The goals of the current application are to understand 1syn oligomer formation and how it relates to disease development in humans and to further explore factors that modify and rescue 1syn aggregation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS063963-06
Application #
8453482
Study Section
Biophysics of Neural Systems Study Section (BPNS)
Program Officer
Sutherland, Margaret L
Project Start
2009-07-15
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
6
Fiscal Year
2013
Total Cost
$323,755
Indirect Cost
$116,883
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
McFarland, Nikolaus R; Dimant, Hemi; Kibuuka, Laura et al. (2014) Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not ?-synuclein-induced neuronal cell loss. PLoS One 9:e86048
Jones, Daryl Rhys; Moussaud, Simon; McLean, Pamela (2014) Targeting heat shock proteins to modulate ?-synuclein toxicity. Ther Adv Neurol Disord 7:33-51
Winslow, Ashley R; Moussaud, Simon; Zhu, Liya et al. (2014) Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain 137:1958-70
Moussaud, Simon; Jones, Daryl R; Moussaud-Lamodière, Elisabeth L et al. (2014) Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener 9:43
Dimant, Hemi; Zhu, Liya; Kibuuka, Laura N et al. (2014) Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One 9:e92098
Kalia, Lorraine V; Kalia, Suneil K; McLean, Pamela J et al. (2013) *-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 73:155-69
Donmez, Gizem; Arun, Anirudh; Chung, Chee-Yeun et al. (2012) SIRT1 protects against *-synuclein aggregation by activating molecular chaperones. J Neurosci 32:124-32
Ebrahimi-Fakhari, Darius; Wahlster, Lara; McLean, Pamela J (2011) Molecular chaperones in Parkinson's disease--present and future. J Parkinsons Dis 1:299-320
Danzer, Karin M; McLean, Pamela J (2011) Drug targets from genetics: alpha-synuclein. CNS Neurol Disord Drug Targets 10:712-23
Kalia, Lorraine V; Kalia, Suneil K; Chau, Hien et al. (2011) Ubiquitinylation of ?-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS One 6:e14695

Showing the most recent 10 out of 16 publications